article thumbnail

Why 2020 Is Pivotal for Microbiome Drug R&D (Or Maybe 2021, Given COVID-19)

Xconomy

Given the number of late-stage and mid-stage studies expected to report data in 2020—assuming they stay on track amid the COVID-19 pandemic—this could be a pivotal year for the field, said Isabelle de Cremoux, CEO and managing partner of Seventure Partners.

Class 138
article thumbnail

Framework Benchmarks Round 22

TechEmpower

synopse I have written a blog post about TFB and object pascal - yes, we added our object pascal framework in round 22! Context and use case determines how you optimize your code. btw: xitca-web (bench code not including dependencies) does not do 2,3,5 and still remains competitive in micro bench can be used as a reference.

Framework 409
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

After Ending Cancer Drug Program, Halozyme Predicts Profits in 2020

Xconomy

Halozyme suffered a setback in November when its investigational pancreatic drug failed a Phase 3 clinical trial , but its CEO says the biotech’s drug delivery technology will make the company profitable as early as the second quarter of this year.

article thumbnail

Got 2020 Clear Vision?

Daradiction

As I reflect upon the past decade and get clear about my vision for my life by 2020 there are a few stories that I would like to share with you: Petunia Pickle Bottom. What effects do you want to create by 2020? Got 2020 Clear Vision? I didn’t find my North Star (community empowerment) until quite recently.

article thumbnail

National Xconomy Awards Now Accepting Nominations for the Best in Biotech

Xconomy

The nomination period for the 2020 National Xconomy Awards is now open. Building on the popularity and strength of the 2017-2019 Boston Xconomy Awards and the 2019 San Diego Xconomy Awards, the 2020 National Xconomy Awards winners will be announced at a Monday, June 8 gala at the Hard Rock Hotel San Diego during. Submit yours today.

San Diego 101
article thumbnail

Flagship Adds $1.1B for New Meds, More AI, & “Health Security”

Xconomy

Flagship Pioneering founder and CEO Noubar Afeyan didn’t know a global pandemic was in the cards for 2020 when he and his team laid out three new thematic areas of focus for the company last fall.

article thumbnail

Bio Roundup: So Long Celgene, RNAi’s Arrival, Pharma in 2020 & More

Xconomy

Bristol-Myers Squibb this week completed its acquisition of Celgene, a $74 billion deal that creates a pharmaceutical juggernaut. And all it took was the largest asset sale ever required by federal antitrust regulators.